CSL Annual Report 2022

US$2.255 billion in reported net profit after tax US$2.22 dividend per share for 2022 CSL Limited Annual Report 2021/22 3 Outlook While I began this note expressing my optimism, I am always wary of the broader environment in which we operate. At the time of writing there are significant geopolitical issues relating to war in the Ukraine, supply chain disruptions, energy security, and inflation. There are no quick fixes to many of these issues, but the vital nature of the products and treatments that CSL produces means we can factor in a level of confidence to our growth plan. I can assure you that we will work to control what is within our control with the people who rely on our vaccines and therapies as our priority. As always, in doing so we will continue to strive to create value for shareholders. I am pleased to report that the total full year dividend per share is US$2.22 per share, which is held constant with the previous financial year. Thank you for your ongoing support of our company. Brian McNamee AO Chair More on CSL.com (Investors > Financial Results and Information)

RkJQdWJsaXNoZXIy MjE2NDg3